Abstract
Human induced pluripotent stem cells (hiPSCs) have great potential as a robust source of progenitors for regenerative medicine. The novel technology also enables the derivation of patient-specific cells for applications to personalized medicine, such as for personal drug screening and toxicology. However, the biological characteristics of iPSCs are not yet fully understood and their similarity to human embryonic stem cells (hESCs) is still unresolved. Variations among iPSCs, resulting from their original tissue or cell source, and from the experimental protocols used for their derivation, significantly affect epigenetic properties and differentiation potential. Here we review the potential of iPSCs for regenerative and personalized medicine, and assess their expression pattern, epigenetic memory and differentiation capabilities in relation to their parental tissue source. We also summarize the patient-specific iPSCs that have been derived for applications in biological research and drug discovery; and review risks that must be overcome in order to use iPSC technology for clinical applications.
Keywords: Differentiation, epigenetic memory, hES cells, iPS cells, personalized medicine, regenerative medicine, reprogramming.
Current Molecular Medicine
Title:Induced Pluripotent Stem Cells (iPSCs) Derived from Different Cell Sources and their Potential for Regenerative and Personalized Medicine
Volume: 13 Issue: 5
Author(s): R. Shtrichman, I. Germanguz and J. Itskovitz- Eldor
Affiliation:
Keywords: Differentiation, epigenetic memory, hES cells, iPS cells, personalized medicine, regenerative medicine, reprogramming.
Abstract: Human induced pluripotent stem cells (hiPSCs) have great potential as a robust source of progenitors for regenerative medicine. The novel technology also enables the derivation of patient-specific cells for applications to personalized medicine, such as for personal drug screening and toxicology. However, the biological characteristics of iPSCs are not yet fully understood and their similarity to human embryonic stem cells (hESCs) is still unresolved. Variations among iPSCs, resulting from their original tissue or cell source, and from the experimental protocols used for their derivation, significantly affect epigenetic properties and differentiation potential. Here we review the potential of iPSCs for regenerative and personalized medicine, and assess their expression pattern, epigenetic memory and differentiation capabilities in relation to their parental tissue source. We also summarize the patient-specific iPSCs that have been derived for applications in biological research and drug discovery; and review risks that must be overcome in order to use iPSC technology for clinical applications.
Export Options
About this article
Cite this article as:
Shtrichman R., Germanguz I. and Eldor J. Itskovitz-, Induced Pluripotent Stem Cells (iPSCs) Derived from Different Cell Sources and their Potential for Regenerative and Personalized Medicine, Current Molecular Medicine 2013; 13 (5) . https://dx.doi.org/10.2174/1566524011313050010
DOI https://dx.doi.org/10.2174/1566524011313050010 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antiplatelet Therapy in TAVI: Current Clinical Practice and Recommendations
Current Pharmaceutical Design Vascular Disease and Insulin-Like Growth Factor-1
Vascular Disease Prevention (Discontinued) The Effects of Pemafibrate in Japanese Patients with Type 2 Diabetes Receiving HMG-CoA Reductase Inhibitors
Endocrine, Metabolic & Immune Disorders - Drug Targets Implication of Gut Microbiota in Human Health
CNS & Neurological Disorders - Drug Targets FXR, A Therapeutic Target for Bile Acid and Lipid Disorders
Mini-Reviews in Medicinal Chemistry Sirtuins and Resveratrol-Derived Compounds: A Model for Understanding the Beneficial Effects of the Mediterranean Diet
Endocrine, Metabolic & Immune Disorders - Drug Targets Single Photon Emission Tomography in the Diagnostic Assessment of Cardiac and Vascular Infectious Diseases
Current Radiopharmaceuticals Coronary Atherosclerosis The Implications of Being a Woman
Current Hypertension Reviews Long-Term Safety and Efficacy of Bapineuzumab in Patients with Mild-to-Moderate Alzheimer’s Disease: A Phase 2, Open-Label Extension Study
Current Alzheimer Research Mesenchymal Stem Cell Therapy for Ischemic Heart Disease: Advances and Challenges
Current Pharmaceutical Design Lung Cancer Brachytherapy: Robotics-Assisted Minimally Invasive Approach
Current Respiratory Medicine Reviews Approaches and Resources for Prediction of the Effects of Non-Synonymous Single Nucleotide Polymorphism on Protein Function and Interactions
Current Pharmaceutical Biotechnology Therapeutic Neovascularization by the Implantation of Autologous Mononuclear Cells in Patients with Connective Tissue Diseases
Current Pharmaceutical Design Editorial (Thematic Issue: Is The Female Heart Exposed To Cardiovascular Disease?)
Current Medicinal Chemistry Cytoprotection by Natural and Synthetic Polyphenols in the Heart: Novel Mechanisms and Perspectives
Current Pharmaceutical Design p53 Peptide Prevents LITAF-Induced TNF-Alpha-Mediated Mouse Lung Lesions and Endotoxic Shock
Current Molecular Medicine Lifestyle Changes and Pharmacological Risk Factor Modification for Effective Vascular Disease Prevention
Vascular Disease Prevention (Discontinued) Dietary Compounds, Epigenetic Modifications and Metabolic Diseases
Current Chemical Biology Glucagon-Like Peptide-1 as a Key Regulator of Lipid and Lipoprotein Metabolism in Fasting and Postprandial States
Cardiovascular & Hematological Disorders-Drug Targets Immunosuppressive and Antiviral Treatment of Inflammatory Cardiomyopathy
Recent Patents on Cardiovascular Drug Discovery